Author
Strobl, M
West, J
Viossat, Y
Damaghi, M
Robertson-Tessi, M
Brown, J
Gatenby, R
Maini, P
Anderson, A
Journal title
Cancer Research
DOI
10.1158/0008-5472.CAN-20-0806
Issue
4
Volume
81
Last updated
2024-03-23T09:03:26.467+00:00
Page
1135-1147
Abstract
Adaptive therapy seeks to exploit intra-tumoral competition to avoid, or at least delay, the emergence of therapy resistance in cancer. Motivated by promising results in prostate cancer, there is growing interest in extending this approach to other neoplasms. As such, it is urgent to understand the characteristics of a cancer which determine whether or not it will respond well to adaptive therapy. A plausible candidate for such a selection criterion is the fitness cost of resistance. In this paper, we study a general but simple mathematical model to investigate whether the presence of a cost is necessary for adaptive therapy to extend the time to progression beyond that of a standard-of-care continuous therapy. Tumor cells were divided into sensitive and resistant populations and we model their competition using a system of two ordinary differential equations based on the Lotka-Volterra model. For tumors close to their environmental carrying capacity a cost was not required. However, for tumors growing far from carrying capacity, a cost may be required to see meaningful gains. Notably, it is important to consider cell turnover in the tumor, and we discuss its role in modulating the impact of a resistance cost. To conclude, we present evidence for the predicted cost-turnover interplay in data from 67 prostate cancer patients undergoing intermittent androgen deprivation therapy. Our work helps to clarify under which circumstances adaptive therapy may be beneficial and suggests that turnover may play an unexpectedly important role in the decision making process.
Symplectic ID
1139933
Favourite
Off
Publication type
Journal Article
Publication date
10 Nov 2020
Please contact us with feedback and comments about this page. Created on 26 Oct 2020 - 16:54.